October 2026 | ISSUE #60

Patient and Family Advisory Council

Cuthbert Lab & Oncology Outcomes

In this Issue

Social Media Initiative
Research Highlights
Study Recruitment
Coming Up

Social Media Initiative

Meet the People of our Patient and Family Advisory Council!

The Cuthbert Lab is excited to introduce a new social media initiative where we spotlight one of our amazing PFAC members on our socials! Through these spotlights, we hope to introduce you as the people behind our research and highlight the important role you play in helping us ensure that our research remains patient- and family-centred. By incorporating the perspectives and priorities of patients and families into our work, you help us make our research more meaningful and relevant to the people it is intended to support! If you are interested in being featured, please send us a photo and answer the following questions:

Short Answer:

1. What is your favourite book?
2. What is your favourite movie or TV show?
3. What is your favourite food or cuisine?
4. What are some of your hobbies or interests?

Long Answer (Please choose ONE of the following):

1. Tell us a little bit about your story and your connection to cancer. What motivates you to be involved with the Cuthbert Lab/Oncology Outcomes Patient and Family Advisory Council?
2. What is your favourite part about being a member of the Cuthbert Lab/Oncology Outcomes Patient and Family Advisory Council?

Based on your responses, we will create a graphic introducing you and share it on our social media platforms as attached.

NOTE: By submitting your responses, you are consenting to being featured on the Cuthbert Lab's social media platforms, including Instagram, Facebook, LinkedIn, X, and Bluesky. If you are uncomfortable with your story or information being shared publicly on social media, please do not submit your responses.


Research Highlights

Oncology Outcomes

Outcomes of hepatocellular carcinoma patients treated in the lenvatinib and immunotherapy era (2018-2021) compared to the sorafenib era (2008-2018).

STUDY PURPOSE

Lenvatinib (LEN) and **atezolizumab + bevacizumab** (A + B) have drastically **changed the treatment paradigm** for **advanced hepatocellular carcinoma** (HCC)



Before these landmark trials, **sorafenib** (SOR) was the **standard first-line treatment** for a decade

Recent clinical trials have shown **improved efficacy** of **newer treatments** when compared to **SOR**



Use **real world evidence** to determine if these **treatments** have translated into **meaningful improvement** in **outcomes for HCC patients over time**



Assess **outcomes** of **HCC patients** treated during the **SOR era** (2008-2018) in **contrast** to those in the **post-SOR era** (2018-2021), of which the predominant first-line treatments were **LEN or A + B**

CONCLUSIONS & FUTURE IMPACT



HCC patients treated in the **post-SOR era** showed **superior**:



Overall Survival (OS)



Progression-free Survival (PFS)



Response Rate (RR)

Compared to patients treated in the **SOR era**

LEN and A+B appear to be **main contributors** to these **improved outcomes**



Efficacy outcomes of **real-world** Canadian advanced HCC patients **closely reflect** those in **clinical trials**

Findings affirm the **tangible progress** made in **improving real-world outcomes** for **HCC patients** through **treatment advancements** over the past 15 years


Click here for full article.

Study Recruitment

Sociodemographic and Psychosocial Patient and Physician Factors in Oncology Treatment Decision-Making

What?

We want to understand how people's backgrounds, identities (including culture, race, and gender), life experiences, and personal beliefs shape how patients and physicians make cancer treatment decisions together.



Who?

This study is open to all eligible adults, with additional male participants currently needed to help meet recruitment goals of balanced enrolment.

<u>If you are</u>:

- 18 or older
- Living in Alberta
- Received a cancer diagnosis in the last 2 years
- Referred to a medical oncologist

We want to hear from you. By sharing your experience, you can help researchers better understand how patients and physicians make treatment decisions together, and how personal backgrounds, beliefs and experiences shape these important conversations.



Contact Madison.Leia@ucalgary.ca to learn more

This study has received ethics approval from the Health Research Ethics Board of Alberta (HREBA.CC-25-0065)

Coming Up

The next newsletter will release in November 2026.
Previous issues of the PFAC newsletter have been posted online: https://www.cuthbertlab.com/advisory-council

Follow us on social media

@cuthbert_Lab | @oncoutcomes

Cuthbert Lab | Oncology Outcomes

@Cuthbert_Lab | @OncOutcomes